25例急性脑梗死患者静脉溶栓治疗

Intravenous Thrombolytic Therapy among 25 Patients with Acute Ischemic Stroke

目的观察重组组织型纤溶酶原激活剂(rt-PA)早期静脉溶栓治疗急性脑梗死的疗效及安全性。方法25例发病时间<3h的急性脑梗死患者接受rt-PA静脉溶栓治疗,剂量(0.6～0.9)mg/kg。溶栓前及溶栓后2h、24h及7d接受美国国立卫生院卒中量表(NIHSS)评分,3个月接受改良Rankin评分,并观察安全性。结果溶栓后7d的NIHSS评分较基线值显著改善(P=0.04),20例完成3个月MRS评估者中,0～1分6例(30%),死亡2例(10%)。症状性脑出血患者2例。基线NIHSS评分高(P=0.002)及完全前循环梗死型(P=0.01)者易发生症状性脑出血。结论早期静脉溶栓治疗急性脑梗死能改善患者的远期预后。

Objective To investigate the efficacy and safety of intravenous recombinant tissue plasminogen activator (rt-PA) in patients with early acute ischemic stroke. Methods Twenty-five patients had been treated by intravenous rt-PA (0.6~0.9)mg/kg within 3 h after onset. Clinical assessment by NIHSS score were obtained before thrombolysis and 2 h, 24 h, 7 d after thrombolysis. Three months later, the MRS scores were also evaluated for assessing the efficacy and safety. Results There was a significant improvement i...